A randomized phase II study of the efficacy and safety of combination of Bevacizumab/Pemetrexed versus Pemetrexed maintenance therapy in First-Line treatment of elderly patients with advanced or recurrent post-operative non-squamous and non-small cell lung cancer who received Bevacizumab / Pemetrexed induction therapy.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jan 2015 Status changed from recruiting to discontinued, according to University Hospital Medical Information Network - Japan.
- 03 Mar 2014 New trial record